Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections

Y Zhu, W Hao, X Wang, J Ouyang… - Medicinal Research …, 2022 - Wiley Online Library
Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important
effector immune defense molecules in multicellular organisms. AMPs exert their …

Fosfomycin: pharmacological, clinical and future perspectives

AC Dijkmans, NV Ortiz Zacarías, J Burggraaf… - Antibiotics, 2017 - mdpi.com
Fosfomycin is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative
activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by …

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

RL Nation, J Li, O Cars, W Couet… - The Lancet infectious …, 2015 - thelancet.com
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …

Self‐assembly of antimicrobial peptides on gold nanodots: against multidrug‐resistant bacteria and wound‐healing application

WY Chen, HY Chang, JK Lu, YC Huang… - Advanced Functional …, 2015 - Wiley Online Library
Photoluminescent gold nanodots (Au NDs) are prepared via etching and codeposition of
hybridized ligands, an antimicrobial peptide (surfactin; SFT), and 1‐dodecanethiol (DT), on …

Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain

E del Barrio-Tofiño, C López-Causapé… - Antimicrobial agents …, 2017 - Am Soc Microbiol
This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility
profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa …

Updated US and European dose recommendations for intravenous colistin: how do they perform?

RL Nation, SM Garonzik, J Li… - Clinical Infectious …, 2016 - academic.oup.com
Abstract Background. The US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have approved updated dose recommendations for intravenous …

Clinical pharmacokinetics and pharmacodynamics of colistin

N Grégoire, V Aranzana-Climent, S Magréault… - Clinical …, 2017 - Springer
In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …

Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America

JA Labarca, MJC Salles, C Seas… - Critical reviews in …, 2016 - Taylor & Francis
Increasing prevalence of carbapenem-resistant Pseudomonas aeruginosa and
Acinetobacter baumannii strains in the nosocomial setting in Latin America represents an …

[HTML][HTML] SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF …

M Tutone, TEB Johansen, T Cai, S Mushtaq… - International Journal of …, 2022 - Elsevier
Urinary tract infections (UTIs) are prevalent worldwide, particularly among women. Their
incidence increases with age, and treatment is increasingly challenging owing to antibiotic …

Structural Modification of Lipopolysaccharide Conferred by mcr-1 in Gram-Negative ESKAPE Pathogens

YY Liu, CE Chandler, LM Leung… - Antimicrobial agents …, 2017 - Am Soc Microbiol
ABSTRACT mcr-1 was initially reported as the first plasmid-mediated colistin resistance
gene in clinical isolates of Escherichia coli and Klebsiella pneumoniae in China and has …